MyFinsight
Home
Blog
About
Cash and cash
equivalents
$16,991K
(-65.31%↓ Y/Y)
Marketable securities
$14,739K
(3.83%↑ Y/Y)
Prepaid expenses and
other current assets
$2,580K
(-27.04%↓ Y/Y)
Total current assets
$34,310K
(-48.57%↓ Y/Y)
Right-of-use asset -
operating lease
$659K
(-45.36%↓ Y/Y)
Other assets
$392K
(-16.95%↓ Y/Y)
Property and equipment,
net
$375K
(-29.25%↓ Y/Y)
Total assets
$35,736K
(-48.15%↓ Y/Y)
Total liabilities and
stockholders equity
$35,736K
(-48.15%↓ Y/Y)
Total stockholders
equity
$24,481K
(-56.87%↓ Y/Y)
Total liabilities
$11,255K
(-7.43%↓ Y/Y)
Accumulated deficit
-$490,347K
(-16.00%↓ Y/Y)
Treasury stock, at cost,
4,522 shares of common...
$3,968K
(0.00%↑ Y/Y)
Accumulated other
comprehensive income
-$7K
(-800.00%↓ Y/Y)
Additional paid-in capital
$518,759K
(7.31%↑ Y/Y)
Total current
liabilities
$11,192K
(0.33%↑ Y/Y)
Operating lease
obligation - non-current...
$63K
(-91.95%↓ Y/Y)
Common stock, 0.001 par
value 325,000,000...
$44K
(51.72%↑ Y/Y)
Accrued expenses
$9,238K
(40.35%↑ Y/Y)
Accounts payable
$1,000K
(105.76%↑ Y/Y)
Operating lease
obligation - current...
$720K
(12.50%↑ Y/Y)
Deferred revenue
$234K
(-90.69%↓ Y/Y)
Back
Back
Balance Sheet
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)
source: myfinsight.com